Видео ютуба по тегу Neoadjuvant Setting

I-SPY2 EOP: neoadjuvant vepdegestrant combinations in HR+ breast cancer
I-SPY2 EOP: neoadjuvant vepdegestrant combinations in HR+ breast cancer
Neoadjuvant immunotherapy strategies for challenging endometrial cancer
Neoadjuvant immunotherapy strategies for challenging endometrial cancer
The benefits of neoadjuvant dual checkpoint inhibition in stage III melanoma
The benefits of neoadjuvant dual checkpoint inhibition in stage III melanoma
What Are Adjuvant, Neoadjuvant, And Metastatic Immunotherapy Settings For Breast Cancer?
What Are Adjuvant, Neoadjuvant, And Metastatic Immunotherapy Settings For Breast Cancer?
NEOAVAX Trial: Neoadjuvant Avelumab and Axitinib for Localized High-Risk RCC
NEOAVAX Trial: Neoadjuvant Avelumab and Axitinib for Localized High-Risk RCC
ALNEO Trial: Neoadjuvant Alectinib in Resectable Stage III ALK+ NSCLC – WCLC 2024 Interim Data.
ALNEO Trial: Neoadjuvant Alectinib in Resectable Stage III ALK+ NSCLC – WCLC 2024 Interim Data.
G.I. E03: Esophagus Part 2: Neoadjuvant & Definitive CCRT
G.I. E03: Esophagus Part 2: Neoadjuvant & Definitive CCRT
JCO at ASCO Annual Meeting: Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC
JCO at ASCO Annual Meeting: Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC
Prof. Patrick Forde on Immunotherapy in the Neoadjuvant & Perioperative Setting for NSCLC
Prof. Patrick Forde on Immunotherapy in the Neoadjuvant & Perioperative Setting for NSCLC
ADCs for the treatment of bladder cancer in the neoadjuvant setting
ADCs for the treatment of bladder cancer in the neoadjuvant setting
Immunotherapy in the neoadjuvant setting of melanoma
Immunotherapy in the neoadjuvant setting of melanoma
Breast Cancer Treatment in a Neoadjuvant Setting
Breast Cancer Treatment in a Neoadjuvant Setting
Emerging neoadjuvant therapies for metastatic melanoma at ESMO 2024
Emerging neoadjuvant therapies for metastatic melanoma at ESMO 2024
Optimizing neoadjuvant and adjuvant therapy for patients undergoing CRS and HIPEC
Optimizing neoadjuvant and adjuvant therapy for patients undergoing CRS and HIPEC
Dr Yee on Neoadjuvant Datopotamab Deruxtecan Plus Durvalumab in Early-Stage Breast Cancer
Dr Yee on Neoadjuvant Datopotamab Deruxtecan Plus Durvalumab in Early-Stage Breast Cancer
Dr Yee on Neoadjuvant Datopotamab Deruxtecan in High-Risk, Early-Stage Breast Cancer
Dr Yee on Neoadjuvant Datopotamab Deruxtecan in High-Risk, Early-Stage Breast Cancer
Intensified dosing of neoadjuvant Foxy-5 for colon cancer in the NeoFox trial
Intensified dosing of neoadjuvant Foxy-5 for colon cancer in the NeoFox trial
Trial updates in neoadjuvant adjuvant therapies for early-stage NSCLC
Trial updates in neoadjuvant adjuvant therapies for early-stage NSCLC
Axillary management for breast cancer in the post-neoadjuvant setting
Axillary management for breast cancer in the post-neoadjuvant setting
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer Guideline
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer Guideline
1 + 1 = 3. Combined Use of Anti-HER2 Agents in the Neoadjuvant Setting
1 + 1 = 3. Combined Use of Anti-HER2 Agents in the Neoadjuvant Setting
Advances in Neoadjuvant IO in MSI-H/dMMR Colorectal Cancer
Advances in Neoadjuvant IO in MSI-H/dMMR Colorectal Cancer
Immunotherapy biomarkers in neoadjuvant breast cancer
Immunotherapy biomarkers in neoadjuvant breast cancer
The case for neoadjuvant pembrolizumab in TNBC
The case for neoadjuvant pembrolizumab in TNBC
ACRO 2023: Clear as Mud: Approaches to Pancreas Cancer in the Neoadjuvant Setting
ACRO 2023: Clear as Mud: Approaches to Pancreas Cancer in the Neoadjuvant Setting